This post was originally published on News-medical.net
You will shortly be re-directed to the publisher's website
In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) has emerged as a promising approach to identify individuals at high risk of disease recurrence and potentially guide adjuvant therapy decisions.